Neurocrine Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary

• Neurocrine Biosciences Inc NBIX.OQ reported quarterly adjusted earnings of $1.06​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 63 cents. The mean expectation of twenty six analysts for the quarter was for earnings of 95 cents per share. Wall Street expected results to range from 63 cents to $1.25 per share.

• Revenue rose 16.5% to $687.50 million from a year ago; analysts expected $652.61 million.

• Neurocrine Biosciences Inc's reported EPS for the quarter was $1.06​.

• The company reported quarterly net income of $107.5 million.

• Neurocrine Biosciences Inc shares had risen by 6.8% this quarter and lost 1.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.4% in the last three months.​

• In the last 30 days, five analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Neurocrine Biosciences Inc is $163.00, about 17.7% above its last closing price of $134.19

This summary was machine generated from LSEG data July 30 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)